Costs of biological treatment of rheumatoid arthritis;Omkostninger til biologisk behandling af leddegigt

Ugeskrift for Laeger

Volumn 171, Issue 19, 2009, Pages 1585-1590

  Rasmussen, Claus ^a   Knudsen, Martin Stausholm ^a   Hansen, Brian Bekker ^a   Lindkvist, Rose Marie ^a  

^a COWI Sundhed og Økonomi ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COST; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG COSTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 65549161880     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Danbio. Sponsorrapport Infliximab, Etanercept, Adalimumab og Rituximab. Rapport nr. 15, marts 2008. København: Danbio, 2008.
2. Lægemiddelstyrelsen, www.medicinpriser.dk (29. august 2007).
3. Produktresumeer for Enbrel (19/11/2007), Humira (17/01/2008) og Remicade (21/12/2007). Dosering og indgivelsesmåde for voksne med reumatoid artritis. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=3236.
4. Danbio. Årsrapport 2006 - Landsdækkende klinisk kvalitetsdatabase for behandling af reumatologiske patienter med biologiske præparater. København: Danbio, 2007.
5. Alban A, Danneskiold-Samsøe B, Christensen JK et al. Sundhedsøkonomi. Principper og perspektiver. København: DSI Institut for Sundhedsvæsen, 1999.
6. NICE technology appraisal guidance 130 Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. London: National Institute of Clinical Excellence, 2007.
7. Kristensen LE, Christensen R, Bliddal H et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review. Scand J Rheumatol 2007;36:411-7.
8. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new indexs of drug effi-cacy in clinical practice. Results of a five-year observational study of treatment with Infliximab and Etanercept among rheumatoid arthritis patients in Southern Sweden. Arthr & Rheum. 2006;54:600-6.
9. Finckh A, Simard JF, Gabay C et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.